NCT03110822 2023-11-01A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsOncotherapeuticsPhase 1 Recruiting134 enrolled